Studies using Ba/F3 transfected with BCR::ABL1 and the K562 CML cell line found that UBE2A mutations contributed to the downregulation of myeloid differentiation pathways [122]. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.